🇺🇸 FDA
Pipeline program

BOOST cells

KIBB01

Phase 2 small_molecule active

Quick answer

BOOST cells for Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease. is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials